fda bans compounded tirzepatide Breaking News: Compounding Pharmacies Take the Fight to the Fifth Circuit The Outsourcing Facilities Association (OFA) has filed an appeal challenging the FDA's decision to restrict compounding pharmacies from producing tirzepatide, the 2026 FDA Rules and News

We understand that weight loss is about more than food choices

Employer Strategies On-Demand Webinars SmithRx Key Takeaways GLP-1s are highly effective for diabetes and obesity but surged demand and costs, use up ~587% and list prices near $1,000/mo, forcing prior auths and spiking employer drug spend

Gallbladder-related adverse events, including cholelithiasis and cholecystitis, have been reported with GLP-1 receptor agonist therapy

However, due to safety concerns and lack of clinical approval, its use for any medical purpose is not recommended at this time

Epinephrine has the shortest half-life of the catecholamines